查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1574311

登革热疫苗市场：按疫苗类型、最终用户、年龄层、疫苗开发阶段、分销管道、给药途径、技术、患者类型 - 2025-2030 年全球预测

Dengue Vaccine Market by Vaccine Type, End User, Age Group, Vaccine Development Stage, Distribution Channel, Route of Administration, Technology, Patient Type - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年登革热疫苗市值为13.8亿美元，预计到2024年将达到15.3亿美元，复合年增长率为11.79%，到2030年将达到30.2亿美元。

全球登革热疫苗市场被认为在对抗登革热方面发挥重要作用，登革热是一种蚊媒热带疾病，每年影响数百万人。预防和治疗解决方案均旨在满足降低登革热发病率和死亡率的公共卫生要求。由于气候变迁、都市化和旅行增加，登革热疫苗在热带和亚热带地区变得越来越流行，因此对登革热疫苗的需求显而易见。应用包括主要针对流行地区青少年和成人的疫苗接种计划。最终用途包括医院、诊所和公共卫生中心，并有可能扩展到旅游中心和旅游中心。

主要市场统计
基准年[2023] 13.8亿美元
预测年份 [2024] 15.3亿美元
预测年份 [2030] 30.2亿美元
复合年增长率（%） 11.79%

有几个因素正在影响市场的成长，包括人们对蚊媒疾病的认识不断提高、政府的免疫措施以及减毒活病毒疫苗和重组疫苗等疫苗技术的进步。机会在于刺激东南亚、拉丁美洲和非洲新兴市场的需求以及扩大全球疫苗覆盖范围。针对各种登革热病毒血清型的多效价疫苗的开发代表着一个重大机会，探索口服和经皮等新型给药系统以提高依从性和可及性也是如此。

挑战包括安全性和有效性方面的监管障碍，特别是在不同人群和血清型中，这可能会阻碍核准过程。此外，分发疫苗和维持低温运输的后勤挑战构成了真正的障碍。疫苗相对昂贵，这可能会限制低收入地区的疫苗接种，并且需要可扩展的生产和定价策略。

创新研究兴趣包括利用 mRNA 和基于载体的技术等尖端平台来开发具有更广泛血清型覆盖范围和更长免疫持续时间的疫苗。此外，探索与蚊虫控制措施的协同效应并将疫苗纳入更广泛的健康策略将有助于实现更全面的疾病管理。市场的本质是动态的，受到技术进步和不断变化的流行病学模式的驱动，需要持续的研究和跨部门合作以实现有影响力的健康成果。

市场动态：揭示快速发展的登革热疫苗市场的关键市场洞察

供需的动态交互作用正在改变登革热疫苗市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球登革热病例增加，感染地区对疫苗的需求增加
    • 政府和非政府组织采取更多倡议来控制和预防登革热疫情
    • 生物技术的快速进展促进了更有效的登革热疫苗的开发
    • 提高大众对登革热疫苗接种重要性的认识和教育宣传活动
  • 市场限制因素
    • 研发和临床试验成本高
  • 市场机会
    • 行销策略的市场开拓旨在提高对登革热疫苗的认识并将其传播给高风险人群
    • 建立官民合作关係以资助和加速研究和推广
    • 使用数位健康工具监测和管理疫苗接种后结果，持续改进
  • 市场问题
    • 疫苗交付的物流问题和疫苗接种犹豫

波特的五力：驾驭登革热疫苗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点，避免潜在的挑战，确保更强大的市场地位。

PESTLE分析：了解登革热疫苗市场的外部影响

外部宏观环境因素在塑造登革热疫苗市场的表现动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解登革热疫苗市场的竞争状况

登革热疫苗市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵登革热疫苗市场供应商绩效评估

FPNV 定位矩阵是评估登革热疫苗市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製登革热疫苗市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，登革热疫苗市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球登革热发生率上升增加了受影响地区对疫苗的需求
      • 政府和非政府组织加强控制和预防登革热疫情
      • 生物技术的快速进展将加速更有效的登革热疫苗的开发
      • 提高大众对登革热疫苗接种重要性的认识和教育宣传活动
    • 抑制因素
      • 研发成本和临床试验成本不断上升
    • 机会
      • 制定有针对性的行销策略，以提高高风险族群对登革热疫苗的认识和采用
      • 建立官民合作关係以资助和加速研究和分发
      • 利用数位健康工具来监测和管理疫苗接种后的结果，以持续改善。
    • 任务
      • 疫苗交付的后勤问题和对疫苗接种的犹豫
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章登革热疫苗市场：依疫苗类型

  • 介绍
  • DNA疫苗
  • 灭活疫苗
  • 减毒活疫苗
  • 重组疫苗
  • 次单位疫苗

第七章登革热疫苗市场：依最终用户分类

  • 介绍
  • 诊所
  • 政府和非政府组织
  • 医院
  • 研究所

第八章登革热疫苗市场：依年龄组

  • 介绍
  • 青年
  • 成人
  • 儿科的

第九章登革热疫苗市场：依疫苗开发阶段划分

  • 介绍
  • 临床试验
  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 临床前

第10章登革热疫苗市场：依分销管道分类

  • 介绍
  • 医院药房
  • 网路药房
  • 零售药房

第十一章登革热疫苗市场：依给药途径

  • 介绍
  • 注射
  • 鼻腔
  • 口服

第十二章登革热疫苗市场：依技术分类

  • 介绍
  • 常规疫苗
    • 裂解病毒疫苗
    • 全病毒疫苗
  • 下一代疫苗
    • 类病毒颗粒

第十三章登革热疫苗市场：依病患类型

  • 介绍
  • 有症状的

第14章美洲登革热疫苗市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十五章亚太登革热疫苗市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十六章 欧洲、中东和非洲登革热疫苗市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十七章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-535C62918799

The Dengue Vaccine Market was valued at USD 1.38 billion in 2023, expected to reach USD 1.53 billion in 2024, and is projected to grow at a CAGR of 11.79%, to USD 3.02 billion by 2030.

The global dengue vaccine market is recognized for its critical role in combating dengue fever, a mosquito-borne tropical disease affecting millions annually. The scope encompasses both prophylactic and therapeutic solutions, addressing the urgent public health need to reduce dengue incidence and mortality. The necessity of the dengue vaccine is underscored by the increasing prevalence of the disease in tropical and subtropical regions, fueled by climate change, urbanization, and increased travel. Applications primarily involve immunization programs targeting adolescents and adults in endemic regions. End-use scope includes hospitals, clinics, and public health centers, with potential expansion into travel centers and tourist hubs.

KEY MARKET STATISTICS
Base Year [2023] USD 1.38 billion
Estimated Year [2024] USD 1.53 billion
Forecast Year [2030] USD 3.02 billion
CAGR (%) 11.79%

Market growth is influenced by several factors, including rising awareness about mosquito-borne diseases, government initiatives for immunization, and advancements in vaccine technologies, such as live attenuated vaccines and recombinant vaccines. Opportunities lie in expanding vaccine coverage globally, stimulating demand across emerging markets in Southeast Asia, Latin America, and Africa. Developing multi-valent vaccines targeting various dengue virus serotypes offers a significant opportunity, as does exploring novel delivery systems, such as oral or transdermal routes, which can enhance compliance and accessibility.

Challenges include regulatory hurdles, particularly concerning safety and efficacy across diverse populations and serotypes, which can impede approval processes. Additionally, logistical issues in vaccine distribution and cold chain maintenance pose practical barriers. The relatively high cost of vaccines can limit access in low-income regions, necessitating scalable production and pricing strategies.

Innovative areas for research include developing vaccines with broader serotype coverage and longer immunity duration, utilizing cutting-edge platforms like mRNA and vector-based technologies. Moreover, exploring synergies with mosquito control initiatives and integrating vaccines into broader health strategies could ensure more comprehensive disease management. The nature of the market is dynamic, driven by technological progress and shifting epidemiological patterns, underscoring the need for continuous research and collaboration across sectors to achieve impactful health outcomes.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Dengue Vaccine Market

The Dengue Vaccine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increased global incidence of dengue fever cases leading to higher demand for vaccines in affected regions
    • Growing government and non-governmental organizations' initiatives to control and prevent dengue outbreaks
    • Rapid advancements in biotechnology facilitating the development of more effective dengue vaccines
    • Rising public awareness and education campaigns about the importance of dengue vaccination
  • Market Restraints
    • High R&D and clinical trial costs
  • Market Opportunities
    • Developing targeted marketing strategies to increase awareness and adoption of dengue vaccines among at-risk populations
    • Establishing public-private partnerships to fund and accelerate dengue vaccine research and distribution
    • Utilizing digital health tools to monitor and manage post-vaccination outcomes for continuous improvement
  • Market Challenges
    • Logistical issues in vaccine delivery and vaccine hesitancy

Porter's Five Forces: A Strategic Tool for Navigating the Dengue Vaccine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Dengue Vaccine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Dengue Vaccine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Dengue Vaccine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Dengue Vaccine Market

A detailed market share analysis in the Dengue Vaccine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Dengue Vaccine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Dengue Vaccine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Dengue Vaccine Market

A strategic analysis of the Dengue Vaccine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Dengue Vaccine Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca, Bharat Biotech, Bio Farma, Biological E. Limited, CSL Limited, CureVac AG, GeneOne Life Science, Inc., GlaxoSmithKline plc, Inovio Pharmaceuticals, Inc., Johnson & Johnson, Medigen Vaccine Biologics Corp., Merck & Co., Inc., Panacea Biotec, PaxVax, Inc., Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, and Vabiotech.

Market Segmentation & Coverage

This research report categorizes the Dengue Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Vaccine Type, market is studied across DNA Vaccines, Inactivated Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, and Subunit Vaccines.
  • Based on End User, market is studied across Clinics, Government and Non-Government Organizations, Hospitals, and Research Institutes.
  • Based on Age Group, market is studied across Adolescent, Adult, and Pediatric.
  • Based on Vaccine Development Stage, market is studied across Clinical Trials, Phase I, Phase II, Phase III, and Pre-Clinical.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Route of Administration, market is studied across Injection, Nasal, and Oral.
  • Based on Technology, market is studied across Conventional Vaccines and Next-Generation Vaccines. The Conventional Vaccines is further studied across Split Virus Vaccines and Whole Virus Vaccines. The Next-Generation Vaccines is further studied across Virus-Like Particles.
  • Based on Patient Type, market is studied across Symptomatic.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increased global incidence of dengue fever cases leading to higher demand for vaccines in affected regions
      • 5.1.1.2. Growing government and non-governmental organizations' initiatives to control and prevent dengue outbreaks
      • 5.1.1.3. Rapid advancements in biotechnology facilitating the development of more effective dengue vaccines
      • 5.1.1.4. Rising public awareness and education campaigns about the importance of dengue vaccination
    • 5.1.2. Restraints
      • 5.1.2.1. High R&D and clinical trial costs
    • 5.1.3. Opportunities
      • 5.1.3.1. Developing targeted marketing strategies to increase awareness and adoption of dengue vaccines among at-risk populations
      • 5.1.3.2. Establishing public-private partnerships to fund and accelerate dengue vaccine research and distribution
      • 5.1.3.3. Utilizing digital health tools to monitor and manage post-vaccination outcomes for continuous improvement
    • 5.1.4. Challenges
      • 5.1.4.1. Logistical issues in vaccine delivery and vaccine hesitancy
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Dengue Vaccine Market, by Vaccine Type

  • 6.1. Introduction
  • 6.2. DNA Vaccines
  • 6.3. Inactivated Vaccines
  • 6.4. Live Attenuated Vaccines
  • 6.5. Recombinant Vaccines
  • 6.6. Subunit Vaccines

7. Dengue Vaccine Market, by End User

  • 7.1. Introduction
  • 7.2. Clinics
  • 7.3. Government and Non-Government Organizations
  • 7.4. Hospitals
  • 7.5. Research Institutes

8. Dengue Vaccine Market, by Age Group

  • 8.1. Introduction
  • 8.2. Adolescent
  • 8.3. Adult
  • 8.4. Pediatric

9. Dengue Vaccine Market, by Vaccine Development Stage

  • 9.1. Introduction
  • 9.2. Clinical Trials
  • 9.3. Phase I
  • 9.4. Phase II
  • 9.5. Phase III
  • 9.6. Pre-Clinical

10. Dengue Vaccine Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. Dengue Vaccine Market, by Route of Administration

  • 11.1. Introduction
  • 11.2. Injection
  • 11.3. Nasal
  • 11.4. Oral

12. Dengue Vaccine Market, by Technology

  • 12.1. Introduction
  • 12.2. Conventional Vaccines
    • 12.2.1. Split Virus Vaccines
    • 12.2.2. Whole Virus Vaccines
  • 12.3. Next-Generation Vaccines
    • 12.3.1. Virus-Like Particles

13. Dengue Vaccine Market, by Patient Type

  • 13.1. Introduction
  • 13.2. Symptomatic

14. Americas Dengue Vaccine Market

  • 14.1. Introduction
  • 14.2. Argentina
  • 14.3. Brazil
  • 14.4. Canada
  • 14.5. Mexico
  • 14.6. United States

15. Asia-Pacific Dengue Vaccine Market

  • 15.1. Introduction
  • 15.2. Australia
  • 15.3. China
  • 15.4. India
  • 15.5. Indonesia
  • 15.6. Japan
  • 15.7. Malaysia
  • 15.8. Philippines
  • 15.9. Singapore
  • 15.10. South Korea
  • 15.11. Taiwan
  • 15.12. Thailand
  • 15.13. Vietnam

16. Europe, Middle East & Africa Dengue Vaccine Market

  • 16.1. Introduction
  • 16.2. Denmark
  • 16.3. Egypt
  • 16.4. Finland
  • 16.5. France
  • 16.6. Germany
  • 16.7. Israel
  • 16.8. Italy
  • 16.9. Netherlands
  • 16.10. Nigeria
  • 16.11. Norway
  • 16.12. Poland
  • 16.13. Qatar
  • 16.14. Russia
  • 16.15. Saudi Arabia
  • 16.16. South Africa
  • 16.17. Spain
  • 16.18. Sweden
  • 16.19. Switzerland
  • 16.20. Turkey
  • 16.21. United Arab Emirates
  • 16.22. United Kingdom

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2023
  • 17.2. FPNV Positioning Matrix, 2023
  • 17.3. Competitive Scenario Analysis
  • 17.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AstraZeneca
  • 2. Bharat Biotech
  • 3. Bio Farma
  • 4. Biological E. Limited
  • 5. CSL Limited
  • 6. CureVac AG
  • 7. GeneOne Life Science, Inc.
  • 8. GlaxoSmithKline plc
  • 9. Inovio Pharmaceuticals, Inc.
  • 10. Johnson & Johnson
  • 11. Medigen Vaccine Biologics Corp.
  • 12. Merck & Co., Inc.
  • 13. Panacea Biotec
  • 14. PaxVax, Inc.
  • 15. Pfizer Inc.
  • 16. Sanofi
  • 17. Serum Institute of India Pvt. Ltd.
  • 18. Sinovac Biotech Ltd.
  • 19. Takeda Pharmaceutical Company Limited
  • 20. Vabiotech

LIST OF FIGURES

  • FIGURE 1. DENGUE VACCINE MARKET RESEARCH PROCESS
  • FIGURE 2. DENGUE VACCINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DENGUE VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DENGUE VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DENGUE VACCINE MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DENGUE VACCINE MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. GLOBAL DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2023 VS 2030 (%)
  • FIGURE 21. GLOBAL DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. AMERICAS DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. AMERICAS DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. UNITED STATES DENGUE VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 25. UNITED STATES DENGUE VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 29. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 30. DENGUE VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 31. DENGUE VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DENGUE VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DENGUE VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DENGUE VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DENGUE VACCINE MARKET DYNAMICS
  • TABLE 7. GLOBAL DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DENGUE VACCINE MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DENGUE VACCINE MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DENGUE VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DENGUE VACCINE MARKET SIZE, BY RECOMBINANT VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DENGUE VACCINE MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DENGUE VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DENGUE VACCINE MARKET SIZE, BY GOVERNMENT AND NON-GOVERNMENT ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DENGUE VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DENGUE VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DENGUE VACCINE MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DENGUE VACCINE MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DENGUE VACCINE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL DENGUE VACCINE MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL DENGUE VACCINE MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL DENGUE VACCINE MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL DENGUE VACCINE MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL DENGUE VACCINE MARKET SIZE, BY PRE-CLINICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL DENGUE VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL DENGUE VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL DENGUE VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL DENGUE VACCINE MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL DENGUE VACCINE MARKET SIZE, BY NASAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL DENGUE VACCINE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL DENGUE VACCINE MARKET SIZE, BY SPLIT VIRUS VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL DENGUE VACCINE MARKET SIZE, BY WHOLE VIRUS VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL DENGUE VACCINE MARKET SIZE, BY VIRUS-LIKE PARTICLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL DENGUE VACCINE MARKET SIZE, BY SYMPTOMATIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 85. CANADA DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 91. MEXICO DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. MEXICO DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 94. MEXICO DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 95. MEXICO DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 96. MEXICO DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED STATES DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED STATES DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED STATES DENGUE VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 122. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 126. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 128. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. CHINA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. CHINA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. CHINA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 132. CHINA DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 133. CHINA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. CHINA DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. CHINA DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 136. CHINA DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 137. CHINA DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 138. CHINA DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. INDIA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. INDIA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. INDIA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 142. INDIA DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 143. INDIA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. INDIA DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. INDIA DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 146. INDIA DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 147. INDIA DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 148. INDIA DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. INDONESIA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. INDONESIA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. INDONESIA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 152. INDONESIA DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 153. INDONESIA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. INDONESIA DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. INDONESIA DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 156. INDONESIA DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 157. INDONESIA DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 158. INDONESIA DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. JAPAN DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. JAPAN DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. JAPAN DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 162. JAPAN DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 163. JAPAN DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. JAPAN DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. JAPAN DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 166. JAPAN DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 167. JAPAN DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 168. JAPAN DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. MALAYSIA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. MALAYSIA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. MALAYSIA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 172. MALAYSIA DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 173. MALAYSIA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. MALAYSIA DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. MALAYSIA DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 176. MALAYSIA DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 177. MALAYSIA DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 178. MALAYSIA DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. PHILIPPINES DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. PHILIPPINES DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. PHILIPPINES DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 182. PHILIPPINES DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 183. PHILIPPINES DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. PHILIPPINES DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 186. PHILIPPINES DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 188. PHILIPPINES DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. SINGAPORE DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. SINGAPORE DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 191. SINGAPORE DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 192. SINGAPORE DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 193. SINGAPORE DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. SINGAPORE DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 195. SINGAPORE DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 196. SINGAPORE DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 197. SINGAPORE DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 198. SINGAPORE DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH KOREA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH KOREA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH KOREA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH KOREA DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH KOREA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH KOREA DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH KOREA DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH KOREA DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. TAIWAN DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. TAIWAN DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 211. TAIWAN DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 212. TAIWAN DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 213. TAIWAN DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 214. TAIWAN DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 215. TAIWAN DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 216. TAIWAN DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 217. TAIWAN DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 218. TAIWAN DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. THAILAND DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. THAILAND DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 221. THAILAND DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 222. THAILAND DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 223. THAILAND DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 224. THAILAND DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 225. THAILAND DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 226. THAILAND DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 227. THAILAND DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 228. THAILAND DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. VIETNAM DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. VIETNAM DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 231. VIETNAM DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 232. VIETNAM DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 233. VIETNAM DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 234. VIETNAM DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 235. VIETNAM DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 236. VIETNAM DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 237. VIETNAM DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 238. VIETNAM DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 250. DENMARK DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. DENMARK DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 252. DENMARK DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 253. DENMARK DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 254. DENMARK DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 255. DENMARK DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 256. DENMARK DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 257. DENMARK DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 258. DENMARK DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 259. DENMARK DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. EGYPT DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. EGYPT DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 262. EGYPT DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 263. EGYPT DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 264. EGYPT DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 265. EGYPT DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 266. EGYPT DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 267. EGYPT DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 268. EGYPT DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 269. EGYPT DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. FINLAND DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 271. FINLAND DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 272. FINLAND DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 273. FINLAND DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 274. FINLAND DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 275. FINLAND DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 276. FINLAND DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 277. FINLAND DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 278. FINLAND DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 279. FINLAND DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. FRANCE DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. FRANCE DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 282. FRANCE DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 283. FRANCE DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 284. FRANCE DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 285. FRANCE DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 286. FRANCE DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 287. FRANCE DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 288. FRANCE DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 289. FRANCE DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. GERMANY DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 291. GERMANY DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 292. GERMANY DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 293. GERMANY DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 294. GERMANY DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 295. GERMANY DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 296. GERMANY DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 297. GERMANY DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 298. GERMANY DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 299. GERMANY DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 300. ISRAEL DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 301. ISRAEL DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 302. ISRAEL DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 303. ISRAEL DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 304. ISRAEL DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 305. ISRAEL DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 306. ISRAEL DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 307. ISRAEL DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 308. ISRAEL DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 309. ISRAEL DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 310. ITALY DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 311. ITALY DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 312. ITALY DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 313. ITALY DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 314. ITALY DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 315. ITALY DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 316. ITALY DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 317. ITALY DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 318. ITALY DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 319. ITALY DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 320. NETHERLANDS DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 321. NETHERLANDS DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 322. NETHERLANDS DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 323. NETHERLANDS DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 324. NETHERLANDS DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 325. NETHERLANDS DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 326. NETHERLANDS DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 327. NETHERLANDS DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 328. NETHERLANDS DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 329. NETHERLANDS DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 330. NIGERIA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 331. NIGERIA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 332. NIGERIA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 333. NIGERIA DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 334. NIGERIA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 335. NIGERIA DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 336. NIGERIA DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 337. NIGERIA DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 338. NIGERIA DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 339. NIGERIA DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 340. NORWAY DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 341. NORWAY DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 342. NORWAY DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 343. NORWAY DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 344. NORWAY DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 345. NORWAY DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 346. NORWAY DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 347. NORWAY DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
  • TABLE 348. NORWAY DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 349. NORWAY DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 350. POLAND DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 351. POLAND DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 352.